Low climate-impact corticosteroid inhalers are as effective as high climate impact inhalers for COPD and asthma outcomes, per ...

Long COVID occurs in approximately a third of COVID-19 survivors, with the CDC estimating one in 13 adults in the United ...

Respiratory medicine is one frontier of the global healthcare landscape which has undergone significant transformations in ...

Throughout his COPD journey, Gordon has learned a lot about his condition ... I noticed my symptoms had improved,” says Gordon. TRELEGY can help improve lung function for a full 24 hours and prevent ...

A rapid decline in lung function is linked to the development of chronic obstructive pulmonary disease (COPD) ...

Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

Distinct patterns of symptom severity among patients with COPD sheds light on the heterogeneous nature of the patients’ ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...

Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...